BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023 at 01:12 am IST
Share
BioGend Therapeutics Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 38.47 million compared to TWD 5.91 million a year ago. Net loss was TWD 30.02 million compared to TWD 34.47 million a year ago. Basic loss per share from continuing operations was TWD 0.26 compared to TWD 0.33 a year ago. Diluted loss per share from continuing operations was TWD 0.26 compared to TWD 0.33 a year ago.
For the six months, sales was TWD 49.28 million compared to TWD 10.88 million a year ago. Net loss was TWD 81.25 million compared to TWD 79.1 million a year ago. Basic loss per share from continuing operations was TWD 0.69 compared to TWD 0.77 a year ago. Diluted loss per share from continuing operations was TWD 0.69 compared to TWD 0.77 a year ago.
BIOGEND THERAPEUTICS CO., LTD. is a medical equipment company mainly engaged in the development of biological aggregate. The Company is mainly engaged in the development and research of high-grade bone filling materials and knee cartilage repair related medical equipment. The Company's main products are BiG-001 which used for long bone biological aggregate, BiG-006 that used for lumbar interbody fusion biological bone, as well as BiG-009.